[
  {
    "ts": null,
    "headline": "GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights",
    "summary": "Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need.EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead’s Livdelzi (seladelpar) and Ipsen’s Iqirvo (elafibranor). These additions to t",
    "url": "https://finnhub.io/api/news?id=924548d7a1df205314ee11a2eb570fea468bafda1d6c666c6d1cea9b9f53a4d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752771600,
      "headline": "GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights",
      "id": 135996916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need.EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead’s Livdelzi (seladelpar) and Ipsen’s Iqirvo (elafibranor). These additions to t",
      "url": "https://finnhub.io/api/news?id=924548d7a1df205314ee11a2eb570fea468bafda1d6c666c6d1cea9b9f53a4d6"
    }
  },
  {
    "ts": null,
    "headline": "Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player",
    "summary": "Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment.Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis\" report has been added to",
    "url": "https://finnhub.io/api/news?id=7081c327c3441b4caf58fbc261e9e840f9d02a82419114a3c9644fda4effee1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752764760,
      "headline": "Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player",
      "id": 135993695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment.Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis\" report has been added to",
      "url": "https://finnhub.io/api/news?id=7081c327c3441b4caf58fbc261e9e840f9d02a82419114a3c9644fda4effee1b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=e5d069d8987b2017149c6ff8b4eea45d1bbfad975400812fa02a005ab3ded0ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752757204,
      "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
      "id": 135993696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=e5d069d8987b2017149c6ff8b4eea45d1bbfad975400812fa02a005ab3ded0ca"
    }
  }
]